AbbVie Partners With Iambic to Accelerate AI‑Driven Drug Discovery Efforts

AbbVie announces partnership with AI firm Iambic to speed drug discovery, stating goal to use machine learning models to identify novel compounds faster than traditional methods. The partnership was announced in a joint press release highlighting the need for faster pipelines amid rising competition.

Iambic will provide its proprietary AI platform, which analyzes large chemical datasets and predicts biological activity, allowing AbbVie researchers to prioritize candidates earlier in the pipeline. The platform leverages deep learning algorithms that have been shown in recent studies to improve hit identification rates.

The Collaboration includes joint research teams, shared data access, and a co‑funded grant to explore AI applications in oncology and immunology, two focus areas for AbbVie’s pipeline. Both companies aim to file joint patents on any AI‑derived molecules emerging from the collaboration within the next two years.

Industry analysts note the deal reflects growing pharma investment in AI, citing trends where AI tools aim to cut development time and cost, though they caution that regulatory approval remains a hurdle.